Navigation Links
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed
Date:10/21/2013

has diabetes and 1.9 million new diagnoses occur per year in people aged 20 years and older.[i] "The acquisition of Depomed's diabetes royalty rights is a significant addition to our income generating assets," said John McLaughlin, chief executive officer of PDL BioPharma. "This acquisition allows PDL to participate in a potentially lengthy, diversified stream of royalties on products in different classes across the diabetes area. Our goal is to be the financial partner of choice to leading life science companies and other institutions seeking to access non-dilutive capital by monetizing their royalty assets, and we are actively looking to expand our portfolio."

Glumetza, a once-daily extended release metformin product approved for the treatment for adults with type 2 diabetes, is licensed by Depomed to Santarus, Inc. in the United States. For the year ended 2012, Depomed reported royalty revenues of $42.8 million based upon net sales of Glumetza by Santarus. PDL will receive Depomed's royalties on net sales of Glumetza of 32 percent for the remainder of 2013 and full year 2014, and 34.5 percent in 2015 and beyond. In the event of generic entry of a Glumetza product in the United States, PDL will share proceeds equally with Santarus based on a gross margin split. In addition to Glumetza royalties due from Santarus, PDL will receive Depomed's royalties due from Valeant Pharmaceuticals for sales in Canada and from LG Life Sciences for sales in Korea.

Janumet XR is Merck's fixed-dose combination product for type 2 diabetes containing sitagliptin, an extended release metformin that was approved by the FDA in February 2012. Depomed granted Merck a license as well as other rights to certain of its patents directed to metformin extended release technology for Janumet XR. PDL will receive Depomed's very low single digit royalty on Merck's net sales of Ja
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PDL BioPharma Provides $60 Million in Financing to LENSAR
2. Global Biopharma Mergers & Acquisition and Deal Making Report 2013: Understanding the Latest Trends to Optimize Future Strategy
3. PDL BioPharma to Present at the 4th Annual Credit Suisse Small/Mid Cap Conference
4. PDL BioPharma Provides Third Quarter 2013 Revenue Guidance of $97 Million
5. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
6. New HAE Drug Candidate from Dyax Produced by Laureate Biopharma
7. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
8. Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc.
9. PDL BioPharma Announces Second Quarter 2013 Financial Results
10. Pre-Market Analysis: MannKind, Galena Biopharma, Ariad Pharma, and Novavax
11. Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2013 On August 7, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology, and medical device ... and the United States , today ... Tel Aviv area of Israel.  ... broad platform of integrated R&D services to local customers. ...
(Date:10/30/2014)... Boston Scientific Corporation (NYSE: BSX ... Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 ... Brennan , executive vice president and chief financial officer, ... approximately 8:00 a.m. PT followed by a question and ... presentation and question and answer session will be available ...
(Date:10/30/2014)... , Oct. 30, 2014   ViaDerma, Inc. ... to bringing new products to market, has recently ... TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic ... that can convert oral medication active ingredients into ... a first aid antibiotic to help prevent skin ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... , FRAZER, Pa., ... announced that it has filed a lawsuit in U.S. District ... of U.S. Patent Nos. 7,132,570 (the ",570 Patent"), 7,297,346 (the ... product NUVIGIL® (armodafinil) Tablets [C-IV]. Cephalon has a three-year ...
... , NEW ... market research report is available in its catalogue: , ... , http://www.reportlinker.com/p0164248/Pharmaceutical-Contract-Manufacturing---Global-Market-Trends.html ... form of increasing competition in generic markets, rising cost ...
Cached Medicine Technology:Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 3Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 2Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 3Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 5
(Date:10/30/2014)... San Diego, Calif. (PRWEB) October 30, 2014 ... no longer mutually exclusive concepts in the medical-grade ... focusing on the development of uniquely potent topical ... Skin Health System ( http://www.RefinitySkinScience.com ) with patented ... highest available glycolic acid concentrations (50% and 70%) ...
(Date:10/30/2014)... 2014 PreDiabetes Centers , the ... shoppers with a supply of sugardown®, a chewable ... post-meal blood sugar spikes. Learning how to control blood ... part of a diabetes prevention plan. , Shoppers who ... complimentary tube of sugardown. The offer expires November 30. ...
(Date:10/30/2014)... CT (PRWEB) October 30, 2014 Radio ... are raising questions about the impact of traditional radio ... marketing method most likely to influence a purchasing decision. ... poll of 525 consumers conducted by radio marketing company ... product categories, isolating the results of respondents who indicated ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... been identified that appear linked to autism spectrum disorders, ... are on their way to discovering up to 1,000 ... Autism spectrum disorders include a range of developmental disabilities ... An estimated one in 68 U.S. children has an ...
(Date:10/30/2014)... 30, 2014 Home Care Assistance – ... of non-medical, in-home senior care, is weighing in on ... health. , The study, performed by the University of ... and 78 over a week-long period and observed how ... physical activity. By examining the structural soundness of the ...
Breaking Medicine News(10 mins):Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3
... Study highlights:, - A blood test recently approved ... better than tests currently used in the,United States., ... mortality in these,patients, which should allow healthcare providers to ... NEW ORLEANS, Nov. 11 A new blood test,identifies ...
... NEW ORLEANS, Nov. 11 A veteran ... Association Howard L.,Lewis Achievement Award for excellence ... Stiles of Freemont, Calif., was honored for ... clinical, economic,political, ethical and cultural implications of ...
... BROOK, Ill., Nov. 11 Over $3.2 million ... days by members of the University,HealthSystem Consortium,s (UHC) ... tool. With the new, easy-to-use UHC,Interactive WorkPlan, materials ... the intuitive reports to identify, analyze, and act ...
... (NEWARK, N.J., Nov. 11, 2008) The F.M. Kirby Foundation ... of Nursing at Rutgers, The State University of New Jersey, ... New Jersey residents. , The grant will also fund the ... research and service in the best academic tradition, said Interim ...
... the treatment of erectile dysfunction and pulmonary hypertension ... of the type-5 phosphodiesterase. The type-5 phosphodiesterase is ... of sildenafil on splanchnic blood flow and portal ... led by Otto Clemmesen from Denmark addresses this ...
... Nov. 11 /PRNewswire-FirstCall/ - SXC Health Solutions Corp.,("SXC" ... SXC), a leading provider of,pharmacy benefits management services, ... the Yale Club in New York City on ... 8:00 a.m. until approximately,11:00 a.m. eastern time and ...
Cached Medicine News:Health News:New Blood Test Better Identifies Heart Failure Patients in ER 2Health News:New Blood Test Better Identifies Heart Failure Patients in ER 3Health News:New Blood Test Better Identifies Heart Failure Patients in ER 4Health News:SpendLINK(TM) Enhancements Help Academic Medical Centers Easily Track Savings Opportunities 2Health News:SXC Health Solutions to host analyst and institutional investor event 2
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
... The determination of Ang ... in monitoring the pharmacological effect ... variety of angiotensin converting enzyme ... II receptor antagonists as well ...
Medicine Products: